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Multiple sclerosis (MS) affects all areas of the brain resulting in both focal and diffuse 
damage. In Phase 3 clinical trials, fingolimod showed significant reductions in both 
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To investigate if the effects of fingolimod 0.5 mg on BVL are mediated exclusively 
through its effects on focal damage or if fingolimod also acts independently in 
reducing diffuse damage. 
Methods 
This was a pooled post-hoc analysis of patients from two Phase 3 studies 
(FREEDOMS [N=1272] and FREEDOMS II [N=1083]), with no evidence of focal 
disease activity as defined by absence of gadolinium-enhancing lesions at baseline 
and new active lesions and clinical relapses at follow-up. The percent brain volume 
change (PBVC), as a measure of diffuse tissue damage, was assessed at Month (M) 
12 and M24 by using the Structural Image Evaluation using Normalization of Atrophy 
(SIENA) method. A regression analysis was performed in the pooled intent-to-treat 
(ITT) population to quantify the treatment effect of fingolimod on BVL vs. placebo 
(PBO) in the overall population (unadjusted model), and whether this effect is 
sustained after adjusting for new active lesions and on-study relapses (adjusted 
model). 
Results 
Of 1088 patients, 638 (PBO, n=127; fingolimod, n=511) at M12 and 450 patients 
(PBO, n=68; fingolimod, n=382) at M24 showed no focal activity. Fingolimod 
significantly reduced PBVC by 65.5% over 12M (fingolimod vs. PBO: -0.16 vs. -0.45; 
p=0.001) and by 48.2% over 24M (-0.42 vs. -0.81; p=0.004). An absolute difference 
in PBVC of -0.27% (p<0.001) in favor of fingolimod vs. PBO over 24M was still 
evident in the pooled ITT population, after adjusting for active lesions and on-study 
relapses. The regression model suggests that 54% (-0.27%/-0.51%) of effects of 
fingolimod on PBVC are independent of its effects on visible focal damage. 
 




The effect of fingolimod on diffuse damage is partly independent of its treatment 
effect on focal damage, suggesting that both inflammatory and neurodegenerative 
components of MS are affected. 
Keywords: Relapsing-remitting Multiple Sclerosis; Focal damage; Diffuse damage; 
Brain Volume loss; Fingolimod 
1. INTRODUCTION 
Multiple sclerosis (MS) is traditionally seen as an inflammatory disease of the central 
nervous system (CNS) that is characterized by the presence of circumscribed 
demyelinated plaques in the cerebral white matter (WM).1, 2 Recent post-mortem 
work has re-emphasized, however, that focal WM lesions are only part of the 
spectrum of MS pathology.3 Alterations are also present in the so-called normal-
appearing WM and in the grey matter,4 confirming earlier pathologic observations 
that the disease process affects not only myelin, but also axons and neurons.3-5  
Magnetic resonance imaging (MRI) is widely used in the management of MS patients 
owing to its high sensitivity in detecting focal WM abnormalities. More recently, 
numerous studies have used MRI-based methods for a computed estimation of the 
brain volume loss (BVL) that accumulates throughout the course of the MS.6 Indeed, 
these volumetric changes have shown great clinical relevance, due to their close 
correlation with patients’ physical disability and cognitive impairment.7, 8  MRI has 
been used to monitor the effects of disease-modifying therapies (DMTs) on brain 
volume.9 
Fingolimod, a sphingosine-1-phosphate (S1P) receptor modulator, has been shown 
in three phase 3 studies to significantly reduce BVL, in addition to the significant 
 
Diffuse Damage_Manuscript   Final draft_24-Sep-2015 
4 
 
effects on MRI measures and on clinical endpoints in RRMS patients.10-12 Moreover, 
a recent post-hoc analysis has suggested a complementary role of MRI lesions and 
BVL as potential surrogates for disability in the short term of clinical trials with 
fingolimod13, 14 supporting the inclusion of BVL as one of the key outcome measures 
in the evaluation of therapeutic effects in RRMS.10, 12   
In this context, it would be important to further evaluate the extent to which the 
effects of fingolimod on BVL are mediated through its well-described impact on focal 
damage (relapses and MRI lesions) alone, or by an additional effect on the diffuse 
damage in the non-lesional tissue. To explore this, we performed two different post-
hoc analyses on the pooled data from the two phase 3, double-blind, randomized, 
FREEDOMS and FREEDOMS II trials: 1) we assessed the percent brain volume 
change (PBVC), as a marker of BVL, in a sub-group of patients with no evidence of 
focal disease activity, defined as absence of both clinical relapses and active lesions; 
2) we quantified the treatment effect of fingolimod versus placebo that is mediated 
exclusively by PBVC measures in a statistical model using the pooled population of 
the two trials.  
2. METHODS 
2.1. Patients and Study Design 
Data from both FREEDOMS (N=1272) and FREEDOMS II (N=1083) were pooled in 
the post-hoc analysis. FREEDOMS and FREEDOMS II (registered with 
ClinicalTrials.gov identifier NCT00289978 and NCT00355134), were placebo-
controlled, double-blind, randomized, phase III studies in relapsing-remitting MS 
(RRMS). The study designs were similar and the inclusion/exclusion criteria of both 
trials have been previously described.10, 12 Briefly, RRMS patients aged 18 to 55 
years, with a score of 0 to 5.5 on the Expanded Disability Status Scale (EDSS) and 
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having one or more relapses in the previous year and/or two or more relapses in the 
previous two years were included. Eligible patients were randomized (1:1:1) to 
receive fingolimod 0.5 mg/day, 1.25 mg/day or placebo for two years. Data of the 
fingolimod 0.5 mg/day, 1.25 mg/day groups were pooled. The trials were both 
conducted in accordance with International Conference on Harmonization Guidelines 
for Good Clinical Practice and the ethical principles of the Declaration of Helsinki. 
The ethics committees and institutional review boards of all participating centers 
approved the study protocols. All participants provided written informed consent 
before any study-related procedures were performed. 
2.2. Statistical Analyses 
For the purpose of this study we performed two types of analyses on pooled data 
from the two trials: 
Analysis 1: We assessed the PBVC, in a sub-group of patients with no evidence of 
focal disease activity, defined as absence of clinical relapses,  gadolinium enhancing 
(Gd+) T1-weighted lesions at study entry and new active lesions (Gd+ T1 lesions 
and/or new/enlarging T2 lesions) during the follow-up period. In both trials, PBVC 
was measured by SIENA (Structural Image Evaluation using Normalization of 
Atrophy)15 at Month 12 and Month 24. This subgroup analysis was conducted to 
determine if there is a difference in BVL between fingolimod-treated and placebo 
patients, who did not have evidence of focal disease activity. PBVC at Month 12 and 
at Month 24 in the subgroup with no activity was compared between treatment arms 
using an ANOVA model. 
Analysis 2: A regression analysis was performed on the pooled population of the two 
trials with complete data on MRI lesions, relapses and PBVC over a 24-month 
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follow-up period, in order to confirm and quantify the treatment effect of fingolimod 
on BVL versus placebo, which are independent from its effect on focal disease 
activity.  
Firstly, an unadjusted regression model was used with treatment as the only factor to 
define the overall treatment effect of fingolimod on PBVC over 2 years (vs. placebo). 
Secondly, an adjusted regression model with treatment, relapses (Yes/No) and 
active lesions (Yes/No) during the treatment period as factors was used to determine 
treatment effect on PBVC after adjusting for on-study relapse and lesion activity.  In 
this way, the relative difference in the treatment effect between the unadjusted and 
the adjusted model represents the effect of fingolimod on PBVC, which is 
independent of its effect on MRI lesions and relapses.  
3. RESULTS 
Analysis 1: Of the pooled patients from FREEDOMS and FREEDOMS II, a subgroup 
of 638 patients (placebo, n=127; fingolimod, n=511) over a total of 1996 patients with 
a PBVC assessment at Month 12, and 450 patients (placebo, n=68; fingolimod, 
n=382) over a total of 1799 patients with a PBVC assessment at Month 24, showed 
no focal disease activity. The baseline characteristics are reported in Table 1.  In 
patients with no focal activity, fingolimod-treated patients had a significant reduction 
in PBVC over 12 months (-0.16% BVL in fingolimod group vs. -0.45% in placebo 
group, difference = -0.29%, 95%CI = [-0.13% ; -0.46%], p=0.001) and on PBVC over 
24 months (-0.42% in fingolimod group vs. -0.81% in placebo group, difference =  
-0.39%, 95%CI = [-0.12 ; -0.66%], p=0.004) vs. placebo patients (Figure 1).  
Analysis 2: In the pooled population with complete data on MRI lesions, relapses and 
PBVC over the follow up period (placebo, n=577; fingolimod, n=1198), the 
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unadjusted regression model estimated the absolute difference in PBVC between 
fingolimod versus placebo at Month 24 to be -0.51% (–0.79% vs. -1.30%; p<0.001; 
Figure 2). A significant effect on PBVC in favor of fingolimod was still evident when 
the model was adjusted for active lesions and on-study relapses, resulting in an 
absolute difference of –0.27% (p<0.001).  The regression model therefore suggests 
that 54% (–0.27%/–0.51%) of the effects of fingolimod on PBVC, used here as a 
measure of BVL, are not directly the result of reducing lesions and relapses.  
4. DISCUSSION 
BVL is a continuous process, occurring throughout the disease course of MS, at 
rates higher than in non-MS subjects.16 BVL correlates well with both current and 
future disability and cognitive decline and, as such, has the potential to be used as 
an outcome measure for evaluating DMTs in the treatment of MS.13, 16 In Phase 3 
studies of fingolimod, BVL correlated with MRI lesions, relapses and disability 
progression. However, the MRI lesions and relapses that represent focal disease 
activity and damage, accounted only for up to 50% of variability in brain volume 
changes, with the rest remaining unexplained, potentially reflecting undetected, 
diffuse damage.10, 13  
In this post-hoc analysis, we assessed whether the treatment effect of fingolimod on 
BVL could be related, at least in part, to its effect on diffuse tissue damage. The 
main working hypothesis was, if MS patients without MRI and clinical signs of focal 
damage in the placebo and the treated arms still show a difference in BVL, it is likely 
that this effect is due to fingolimod’s activity on pathological processes affecting non-
lesional tissue. Furthermore, we assessed the ‘residual’ treatment effect of 
fingolimod on BVL, not explained by measurable focal disease activity, by comparing 
unadjusted and adjusted models for relapses and new/enlarging T2 lesions. The 
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results of both analyses clearly showed that there is a significant portion of the 
treatment effect of fingolimod that is not explained by its effect on lesions/relapses 
and may be associated exclusively to diffuse BVL. 
Several lines of evidence suggest that MS is not simply a focal demyelinating 
disease and that macroscopic lesions are just the tip of the iceberg of MS pathology. 
Indeed, the normal-appearing brain is profoundly abnormal, with a diffuse 
pathological process that appears to be distributed throughout the whole central 
nervous system.3, 17 In such a context, the diffuse damage seems to occur, at least in 
part, independently from pathological changes within WM plaques.1, 18 This strongly 
suggests that the brain of MS patients is affected by pathological changes in a more 
global sense.3  
Numerous neuroimaging studies have used MRI-derived methods to assess BVL in 
MS as a measure of diffuse tissue damage.6, 19 They have consistently shown that 
BVL can be observed from the earliest stages of MS and accumulates steadily over 
the course of the disease. Although in most studies significant BVL has been 
interpreted as largely due to the neurodegenerative processes occurring in MS,20 it 
must be stressed that, in a complex disease such as MS, this may reflect different 
pathological substrates of both neuroinflammatory and neurodegenerative origins. 
They certainly include i) the shrinkage of WM lesions due to the loss of myelin, 
oligodendrocytes and axons and the contraction of astrocyte volume occurring 
during lesion maturation ii) the neuronal and glial loss in cortical grey matter (GM) 
lesions and iii) the Wallerian degeneration resulting from axonal transection in WM 
and GM lesions. The progressive volume loss occurring throughout the whole brain, 
however, is likely also the consequence of the diffuse inflammation, microglia 
activation and axonal injury occurring in the normal-appearing brain independently 
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from focal demyelination. Interestingly, in preclinical studies fingolimod has 
demonstrated the potential to act on at least some of these mechanisms, 
augmenting remyelination after toxin-induced demyelination, enhancing 
differentiation of oligodendrocyte progenitor cells and helping survival of mature 
oligodendrocytes, reducing astrogliosis and diminishing microglial activation.18, 21, 22   
In the present analysis, we made an attempt to disentangle the complex RRMS 
pathology. Results clearly showed that a significant portion of the treatment effect on 
BVL is present independently of its effect on clinical and MRI measures of active, 
focal damage. Whether this is due to a direct, neuroprotective effect of fingolimod via 
S1P receptor modulation on neural cells,22-24 and/or due to its immune-mediated 
effects leading to the interruption of the destructive link between inflammation and  
neurodegeneration and pro-inflammatory S1P signaling cascade in the CNS partly 
involving astrocytes,3, 25-27 cannot be established here.  
5. CONCLUSION 
By showing a significant treatment effect of fingolimod on BVL, which is independent 
of its effect on MRI lesions and relapses, the present study provides new evidence of 
the important paradigm shift that has taken place in our understanding of the disease 
process in MS: the disease is not only due to focal inflammatory WM lesions, but 
involves more subtle and diffuse damage throughout the whole brain. This leads to 
the immediate need of targeting MS treatment not only to focal inflammatory lesions 
but also to the neurodegeneration that occurs. In this context, MRI-based 
measurements of brain volume are paramount to assess and monitor the effects of 
DMTs that could meet this target. 
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Figure Legends: 
Figure 1. Subgroup analysisa: Fingolimod treatment effect on percent brain volume 
change in patients with no baseline Gd+ lesions, no relapses and no new active   
lesions, at 12 and 24 months 
aIncludes patients treated with both doses (0.5 mg and 1.25 mg) 
CI, confidence interval 
 
Figure 2. Regression analysisa: Fingolimod treatment effect on diffuse damage is 
still apparent when adjustingb for focal damage 
aIncludes patients treated with both doses (0.5 mg and 1.25 mg) 
bAdjusted for new active lesions and on-study relapses 
CI, confidence interval 
 
 




Table 1: Baseline characteristics  
Characteristic 
Patients with no focal 
activity at Month 12  
(N=638) 
Patients with no focal 
activity at Month 24  
(N=450) 
Age, years  41.2±8.5  41.5±8.5 
Women,(%)  76  74 
Time since first 
symptoms of MS 
 10.3±8.3  10.3±8.1 
No history of disease-
modifying treatment (%) 
 40  38 
Relapses within 
previous 2 years, n 
 2.02±1.29  1.98±1.21 
EDSS score (median, 
range) 
 2.0  (0-5.5)  2.0 (0-5.5) 




 3526±5356  3344±4954 









 1519±79  1519±79 
Data are mean ± SD unless otherwise stated 
EDSS, Expanded Disability Status Scale; MS, multiple sclerosis, SD, standard deviation. 
Patients pooled from FREEDOMS and FREEDOMS II. 
Figure 1:  
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 Fingolimod treatment compared to placebo, resulted in a significant reduction of brain 
volume loss (BVL) over 12 months and 24 months. 
 The effect of fingolimod on BVL is partially independent of its effect on focal damage 
(MRI lesions and relapses). 
 This analysis provides additional evidence that, both inflammatory and 
neurodegenerative components are involved in multiple sclerosis disease processes. 
 
